Revmoxicam (meloxicam) ampoules 1% 1.5 ml. N3


Short- term symptomatic treatment of acute attacks of rheumatoid arthritis and ankylosing spondylitis, when oral and rectal routes of administration can not be applied.



Composition and form of release Revmoxicam 
Main active ingredient: meloxicam.
Auxiliary components: meglumine, glycine, poloxamer, glycofurol, sodium chloride, sodium hydroxide, water for injection.
It is produced in the form of a solution for injection, in ampoules of 1.5 ml.
1 ml of the drug contains 10 mg of meloxicam.

Pharmacological properties Revmoxicam 
This drug belongs to the group of non-steroidal drugs for the treatment of certain diseases in orthopedics.

The effect of the drug is explained by the characteristics of its main active ingredient. The main active ingredient is meloxicam.
Meloxicam is a non-steroidal anti-inflammatory drug. It belongs to the group of oxicams, similar in quality to piroxicams.
It has anti-inflammatory, analgesic, antipyretic and antipyretic effects.
Has a property similar to other anti-inflammatory nonsteroidal drugs – to inhibit the biosynthesis of prostaglandins. The latter play the role of mediators of the inflammatory process. Accordingly, their inhibition reduces the inflammatory process.
Most often it is used as an analgesic for dysmenorrhea, acute attacks of joint and operational pain, accompanied by inflammatory processes.

Indications Revmoxicam 
This drug is used for the treatment of inflammatory and degenerative diseases of the joints, which are accompanied by intense pain syndrome, such as rheumatoid arthritis, acute arthritis, chronic polyarthritis, ankylosing spondylitis.
Also, the drug is used to eliminate pain in osteochondrosis and radiculitis.
It is especially effective in an acute attack of rheumatoid arthritis and ankylosing spondylitis, when oral forms cannot be used.

The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
Also contraindicated in patients, patients with a tendency to gastrointestinal bleeding, cerebrovascular bleeding, with severe renal or hepatic insufficiency and severe heart failure.

Application during pregnancy and lactation
This drug is contraindicated in the treatment of pregnant women.
If it is necessary to use the drug, if a woman is lactating, then breastfeeding should be suspended for the duration of treatment.

Method of administration and dosage
It is intended for use in orthopedics, intramuscularly, in the form of injections.
In the treatment of arthrosis in the acute stage, the patient is administered 7.5 mg of the drug 1 time per day. If necessary, it is possible to increase the dose to 15 mg per dose (the maximum possible dose per day).
In the treatment of ankylosing spondylitis and rheumatoid arthritis, 15 mg of the drug is prescribed once a day.
With positive dynamics of the disease, the dose of meloxicam can be reduced to 7.5 mg.
The correction of the duration of treatment, dosages and treatment regimens is determined by the attending physician individually, depending on the individual indicators of the course of the disease.

Overdose is accompanied by the development of nausea, vomiting, drowsiness, pain in the epigastric region.
When taking large doses of the drug, the patient may experience an increase in blood pressure, impaired liver and kidney function, respiratory depression, convulsions, collapse, coma and respiratory arrest.
To eliminate the symptoms of an overdose, the patient is treated with symptomatic treatment, and also prescribed the intake of enterosorbents and drinking plenty of fluids.
In the course of studies, it was found that three times intake of cholestyramine significantly increases the rate of elimination of meloxicam.

Side effects
The drug is usually well tolerated. In cases of hypersensitivity, reactions such as:

  • nausea, vomiting, diarrhea;
  • rash, dermatitis, allergic urticaria.

The use of the drug may also be accompanied by the development of leukopenia, anemia, visual impairment, allergic reactions, headaches, confusion, epigastric pain, esophagitis.
Possible exacerbations of stomach ulcers, stomatitis, gastrointestinal bleeding, kidney malfunction, mucosal edema, liver dysfunction and hepatitis.

Storage conditions and periods
Expiration date – 3 years from the date of manufacture indicated on the package.
Storage temperature should not be below 8 and above 25 ° C.